Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
259 participants
Study Classification
OBSERVATIONAL
Study Start Date
1999-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Seinäjoki Adult Asthma Study is a single-centre 12-year follow-up study of a total cohort of 259 patients having new-onset asthma that was diagnosed at adult age. The study was divided in two parts: the collection of the original cohort (phase I;n=259) and follow-up visit (phase II; n=203). The aim of this study is to increase the understanding on the diagnostics and diagnostic process, organisation of the long-term asthma care, therapeutic outcomes, prognosis and the factors affecting the prognosis of new-onset asthma diagnosed at adult age.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
NCT05270278
Asthma; Eosinophilic
Asthma Chronic
Bronchial Asthma
+1 more
COMPLETED
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
NCT06299306
Asthma, Bronchial
TERMINATED
Observational Study Regarding Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients
NCT00557141
Asthma
UNKNOWN
Inhaler Adherence in Severe Unstable Asthma
NCT02307669
Asthma
UNKNOWN
NA
Cell Distribution in Induced Sputum in Patients With Asthma
NCT01543516
Bronchial Asthma With eNO-levels Greater Than 30 ppB
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At baseline visit the diagnostic studies performed were: spirometry, PEF (peak expiratory flow) follow-up, other respiratory physiology measurements, laboratory, skin-prick, AQ20 (Airways questionnaire 20), 15D, background data. At follow-up visit, asthma status, co-morbidities (chronic rhinitis or obstructed nose, allergic rhinitis or conjunctivitis, diabetes, hypertension, coronary heart disease, COPD (chronic obstructive pulmonary disease) and any other patient-reported disease), medication (including medication to other diseases and the disease treated), control, severity and lung function were evaluated. In addition to the data gathered at these visits, data on asthma follow-up visits, exacerbations, hospitalisations, possible occupationally induced asthma and prescribed asthma medication were collected from hospital clinics, primary health care, occupational health care and private practices for the whole 12-year follow-up period. In addition, the use of medication that was realised, i.e., medication bought from pharmacy, will be retrieved. In addition to asthma-specific factors, data include occupational, lifestyle and socioeconomic factors at the follow-up visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Asthma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of new-onset asthma made by a respiratory specialist
* Diagnosis confirmed by at least one of the following objective lung function measurements
* FEV1 (forced expiratory volume in one second) reversibility in spirometry of at least 15% and 200 ml
* Diurnal variability (⩾20%) or repeated reversibility (⩾15%/60 l/min) in PEF follow-up
* A significant decrease in FEV1 (15%) or PEF (20%) in response to exercise or allergen
* A significant reversibility in FEV1 (at least 15% and 200 ml) or significant mean PEF in response to a trial with oral or inhaled glucocorticoids
* Symptoms of asthma
* Age ≥15 years
* Diagnosis confirmed by at least one of the following objective lung function measurements
* FEV1 (forced expiratory volume in one second) reversibility in spirometry of at least 15% and 200 ml
* Diurnal variability (⩾20%) or repeated reversibility (⩾15%/60 l/min) in PEF follow-up
* A significant decrease in FEV1 (15%) or PEF (20%) in response to exercise or allergen
* A significant reversibility in FEV1 (at least 15% and 200 ml) or significant mean PEF in response to a trial with oral or inhaled glucocorticoids
* Symptoms of asthma
* Age ≥15 years
Exclusion Criteria
* Physical or mental inability to provide signed informed consent
* Diagnosis of asthma below the age of 15 years
* Diagnosis of asthma below the age of 15 years
Minimum Eligible Age
15 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seinajoki Central Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hannu Kankaanranta
Professor and Head of Respiratory Medicine
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hannu Kankaanranta, Professor
Role: PRINCIPAL_INVESTIGATOR
Seinajoki Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Respiratory Medicine, Seinäjoki Central Hospital
Seinäjoki, , Finland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Finland
References
Explore related publications, articles, or registry entries linked to this study.
Kankaanranta H, Ilmarinen P, Kankaanranta T, Tuomisto LE. Seinajoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care. NPJ Prim Care Respir Med. 2015 Jun 25;25:15042. doi: 10.1038/npjpcrm.2015.42. No abstract available.
Reference Type
BACKGROUND
Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma. Mediators Inflamm. 2015;2015:514868. doi: 10.1155/2015/514868. Epub 2015 Oct 11.
Reference Type
BACKGROUND
Tuomisto LE, Ilmarinen P, Kankaanranta H. Prognosis of new-onset asthma diagnosed at adult age. Respir Med. 2015 Aug;109(8):944-54. doi: 10.1016/j.rmed.2015.05.001. Epub 2015 May 21.
Reference Type
BACKGROUND
Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm. 2016;2016:3690628. doi: 10.1155/2016/3690628. Epub 2016 Apr 26.
Reference Type
BACKGROUND
Kankaanranta H, Tuomisto LE, Ilmarinen P. Age-specific incidence of new asthma diagnoses in Finland. J Allergy Clin Immunol Pract. 2017 Jan-Feb;5(1):189-191.e3. doi: 10.1016/j.jaip.2016.08.015. Epub 2016 Oct 17. No abstract available.
Reference Type
BACKGROUND
Tuomisto LE, Ilmarinen P, Niemela O, Haanpaa J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: Seinajoki Adult Asthma Study. Respir Med. 2016 Aug;117:223-9. doi: 10.1016/j.rmed.2016.06.017. Epub 2016 Jun 23.
Reference Type
RESULT
Ilmarinen P, Tuomisto LE, Niemela O, Danielsson J, Haanpaa J, Kankaanranta T, Kankaanranta H. Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. Eur Respir J. 2016 Oct;48(4):1052-1062. doi: 10.1183/13993003.02198-2015. Epub 2016 Aug 18.
Reference Type
RESULT
Tommola M, Ilmarinen P, Tuomisto LE, Haanpaa J, Kankaanranta T, Niemela O, Kankaanranta H. The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J. 2016 Nov;48(5):1298-1306. doi: 10.1183/13993003.00850-2016. Epub 2016 Sep 22.
Reference Type
RESULT
Ilmarinen P, Tuomisto LE, Niemela O, Tommola M, Haanpaa J, Kankaanranta H. Cluster Analysis on Longitudinal Data of Patients with Adult-Onset Asthma. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):967-978.e3. doi: 10.1016/j.jaip.2017.01.027. Epub 2017 Apr 25.
Reference Type
RESULT
Tommola M, Ilmarinen P, Tuomisto LE, Lehtimaki L, Haanpaa J, Niemela O, Kankaanranta H. Differences between asthma-COPD overlap syndrome and adult-onset asthma. Eur Respir J. 2017 May 1;49(5):1602383. doi: 10.1183/13993003.02383-2016. Print 2017 May.
Reference Type
RESULT
Tommola M, Ilmarinen P, Tuomisto LE, Kankaanranta H. Concern of underdiagnosing asthma-COPD overlap syndrome if age limit of 40 years for asthma is used. Eur Respir J. 2017 Aug 3;50(2):1700871. doi: 10.1183/13993003.00871-2017. Print 2017 Aug. No abstract available.
Reference Type
RESULT
Vahatalo I, Ilmarinen P, Tuomisto LE, Niemela O, Kankaanranta H. Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study. Respir Med. 2018 Apr;137:70-76. doi: 10.1016/j.rmed.2018.02.025. Epub 2018 Mar 2.
Reference Type
RESULT
Ilmarinen P, Tuomisto LE, Niemela O, Kankaanranta H. Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma. J Allergy Clin Immunol Pract. 2019 Jan;7(1):165-174.e4. doi: 10.1016/j.jaip.2018.05.032. Epub 2018 Jun 9.
Reference Type
RESULT
Nordman L, Vahatalo I, Tuomisto LE, Niemela O, Tommola M, Lehtimaki L, Ilmarinen P, Kankaanranta H. Risk factors for asthma exacerbations. J Allergy Clin Immunol Glob. 2025 Jun 21;4(3):100520. doi: 10.1016/j.jacig.2025.100520. eCollection 2025 Aug.
Reference Type
DERIVED
Takala J, Vahatalo I, Tuomisto LE, Niemela O, Ilmarinen P, Kankaanranta H. Participation in scheduled asthma follow-up contacts and adherence to treatment during 12-year follow-up in patients with adult-onset asthma. BMC Pulm Med. 2022 Feb 15;22(1):63. doi: 10.1186/s12890-022-01850-1.
Reference Type
DERIVED
Ilmarinen P, Vahatalo I, Tuomisto LE, Niemela O, Kankaanranta H. Long-term adherence to inhaled corticosteroids in clinical phenotypes of adult-onset asthma. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3503-3505.e3. doi: 10.1016/j.jaip.2021.04.057. Epub 2021 May 30. No abstract available.
Reference Type
DERIVED
Ilmarinen P, Pardo A, Tuomisto LE, Vahatalo I, Niemela O, Nieminen P, Kankaanranta H. Long-term prognosis of new adult-onset asthma in obese patients. Eur Respir J. 2021 Apr 1;57(4):2001209. doi: 10.1183/13993003.01209-2020. Print 2021 Apr.
Reference Type
DERIVED
Tommola M, Won HK, Ilmarinen P, Jung H, Tuomisto LE, Lehtimaki L, Niemela O, Kim TB, Kankaanranta H. Relationship between age and bronchodilator response at diagnosis in adult-onset asthma. Respir Res. 2020 Jul 13;21(1):179. doi: 10.1186/s12931-020-01441-w.
Reference Type
DERIVED
Ilmarinen P, Juboori H, Tuomisto LE, Niemela O, Sintonen H, Kankaanranta H. Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma. Sci Rep. 2019 Nov 6;9(1):16107. doi: 10.1038/s41598-019-52361-9.
Reference Type
DERIVED
Tommola M, Ilmarinen P, Tuomisto LE, Lehtimaki L, Niemela O, Nieminen P, Kankaanranta H. Cumulative effect of smoking on disease burden and multimorbidity in adult-onset asthma. Eur Respir J. 2019 Sep 5;54(3):1801580. doi: 10.1183/13993003.01580-2018. Print 2019 Sep. No abstract available.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCH-2000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma
NCT01227070
COMPLETED
Adult Arm of DZL All Age Asthma Cohort (ALLIANCE)
NCT02419274
RECRUITING
A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)
NCT04808518
COMPLETED
Cluster-Randomized Asthma FeNO Trial
NCT05853809
UNKNOWN
NA
The Prevalence Of Small Airways Dysfunction In Asthma Patients And The Impact On The Asthma Control
NCT04375995
UNKNOWN
NA
To Evaluate the Use of ASTHMA IQ in a Primary Care Setting
NCT01296477
COMPLETED
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885
ACTIVE_NOT_RECRUITING
International Severe Asthma Registry: Canadian Cohort
NCT04045587
RECRUITING
Study In Asthma Control
NCT00273026
TERMINATED
PHASE4
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
NCT02537691
COMPLETED
PHASE4
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma
NCT01078688
COMPLETED
General Risk Factors and Inflammatory Determinants in Older Patients With Asthma
NCT03278561
COMPLETED
Comparison of Biologicals in Treatment of Severe Asthma
NCT04158050
COMPLETED
Diagnostics and Quality of Life With EIA and EILO
NCT03550456
COMPLETED
Progression of Airway Obstruction in Childhood Asthma
NCT00873873
COMPLETED
Predicting the Diagnosis of Asthma
NCT00620334
COMPLETED
Phenotyping Disease Severity in Asthma
NCT05078021
RECRUITING
Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver
NCT00272727
COMPLETED
NA
Impact of Adult Asthma
NCT00005564
COMPLETED
Social Support and Education in Asthma Follow-up (SSEA)
NCT00149500
COMPLETED
NA
Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma
NCT06223581
NOT_YET_RECRUITING
CARE FOR ALL：an Evaluation of an Asthma QIP
NCT05440097
COMPLETED
PHASE4
A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype
NCT06621056
RECRUITING
Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting
NCT02640742
COMPLETED
Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze
NCT01982162
COMPLETED